National Research CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
NRC Health Director Donald Berwick was granted restricted stock units valued at $150,000, vesting in 2027.
NASDAQ
NRC Health Director Parul Bhandari was granted restricted stock units valued at $150,000, vesting in 2027.
NASDAQ
NRC Health Director Stephen H. Lockhart was granted restricted stock units valued at $150,000, vesting in 2027.
NASDAQ
NRC Health Director John N. Nunnelly was granted restricted stock units valued at $150,000, vesting in 2027.
NASDAQ
NRC Health Director Penny Ann Wheeler was granted restricted stock units valued at $150,000, vesting in 2027.
NASDAQ
National Research Corp Executive Vice President Jason Russell Rau was granted 60,000 restricted shares vesting over three years.
NASDAQ
National Research Corp's EVP & CFO, Shane R. Harrison, acquired 8,000 shares of common stock indirectly through an IRA.
NASDAQ
National Research Corp's EVP & CFO, Shane R. Harrison, disposed of 21,271 common shares to cover tax withholding, retaining 150,729 shares.
NASDAQ
David Burik, EVP of Strategic Insights at National Research Corp, received a grant of 100,000 restricted common shares under the company's 2025 Omnibus Incentive Plan.
NASDAQ
National Research Corp's Chairman, Michael D. Hays, exercised 9,145 employee stock options at $15.23 per share.
NASDAQ
Helen Hrdy, EVP & COO of National Research Corp, exercised stock options and subsequently sold a portion of the shares for tax purposes.
NASDAQ
John N. Nunnelly, a Director at National Research Corp, received 22,625 stock options as part of the company's 2025 Omnibus Incentive Plan.
NASDAQ
National Research Corp Director Penny Ann Wheeler received 22,625 stock options with an exercise price of $11.61, exercisable from October 17, 2025.
NASDAQ
National Research Corp. Director Donald M. Berwick received a grant of 22,625 stock options with an exercise price of $11.61, exercisable from October 17, 2025.
NASDAQ
Shane R. Harrison, Executive Vice President and Chief Financial Officer of National Research Corp, was granted 172,000 restricted shares of common stock.
NASDAQ
National Research Corp's Chief Accounting Officer, Jordan Nicole Freeman, acquired 771 shares of common stock at $12.97 per share.
NASDAQ
Form 4: National Research Corp CEO Trent Green Receives 500,000 Share Grant Under 2025 Incentive Plan
National Research Corporation's Chief Executive Officer, Trent S. Green, was granted 500,000 shares of common stock under the company's 2025 Omnibus Incentive Plan.
NASDAQ
Director Patrick E. Beans of National Research Corp reports purchasing 2,500 shares of common stock at an average price of $13.5895.
NASDAQ
Director Parul Bhandari was granted stock options for 34,917 shares of National Research Corp (NRC) at an exercise price of $13.09 on May 7, 2025, according to a Form 4 filing.
NASDAQ
Penny Ann Wheeler, a director of National Research Corporation, reports the acquisition of stock options in a recent SEC filing.
NASDAQ
John N. Nunnelly, a director of National Research Corp, reports the acquisition of stock options.
NASDAQ
Director Donald Berwick reports the acquisition of stock options in National Research Corporation.
NASDAQ
Director Stephen H. Lockhart acquired 34,917 stock options in National Research Corp on May 7, 2025, as part of an annual grant.
NASDAQ
Common Property Trust reports acquiring beneficial ownership of 4,755,317 shares of National Research Corp common stock due to a trust decanting on December 31, 2024.
NASDAQ
Form 4: Amandla MK Trust Transfers Ownership of National Research Corp Shares to Common Property Trust
Amandla MK Trust reports a change in beneficial ownership of National Research Corp shares, transferring its holdings to Common Property Trust.
NASDAQ
Patrick E. Beans, a director of National Research Corp, reports gifting transactions that altered his beneficial ownership of the company's common stock.
NASDAQ
Andrew Monnich, Chief Corp. Development Officer of National Research Corporation, acquired 100,000 shares of common stock on April 7, 2025.
NASDAQ
Helen Hrdy, Chief Operating Officer of National Research Corporation, reports the acquisition of 100,000 shares of common stock on April 7, 2025.
NASDAQ
National Research Corp's CEO, Michael D. Hays, was granted 11,021 stock options on January 10, 2025, which will become fully exercisable on January 10, 2030.
NASDAQ
National Research Corp's CEO, Michael D. Hays, exercised stock options and disposed of shares on January 2, 2025.